Viral vectors remain the most efficient and popular in deriving induced pluripotent stem cells (iPSCs). For translation, it is important to silence or remove the reprogramming factors after induction of pluripotency. In this study, we design an excisable loxP-flanked lentiviral construct that a) includes all the reprogramming elements in a single lentiviral vector expressed by a strong EF-1α promoter; b) enables easy determination of lentiviral titer; c) enables transgene removal and cell enrichment using LoxP-site-specific Cre-recombinase excision and Herpes Simplex Virus-thymidine kinase/ganciclovir (HSV-tk/gan) negative selection; and d) allows for transgene excision in a colony format. A reprogramming efficiency comparable to that reported in the literature without boosting molecules can be consistently obtained. To further demonstrate the utility of this Cre-loxP/HSV-tk/gan strategy, we incorporate a non-viral therapeutic transgene (human blood coagulation Factor IX) in the iPSCs, whose expression can be controlled by a temporal pulse of Cre recombinase. The robustness of this platform enables the implementation of an efficacious and cost-effective protocol for iPSC generation and their subsequent transgenesis for downstream studies.
References
[1]
Takahashi K, Yamanaka S (2006) Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell 126: 663–676.
[2]
Urbach A, Bar-Nur O, Daley GQ, Benvenisty N (2010) Differential Modeling of Fragile X Syndrome by Human Embryonic Stem Cells and Induced Pluripotent Stem Cells. Cell Stem Cell 6: 407–411.
[3]
Marchetto MCN, Carromeu C, Acab A, Yu D, Yeo GW, et al. (2010) A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells. Cell 143: 527–539.
[4]
Ebert AD, Lorson CL, Mattis VB, Rose FF Jr, Svendsen CN, et al. (2009) Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457: 277+.
[5]
Adler ED, Ang Y-S, Carvajal-Vergara X, Chang B, Cohen N, et al. (2010) Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465: 808+.
[6]
Chambers SM, Fasano CA, Ganat YM, Kim H, Lee G, et al. (2009) Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 461: 402+.
[7]
Arbel G, Boulos M, Caspi O, Feldman O, Gepstein A, et al. (2011) Modelling the long QT syndrome with induced pluripotent stem cells. Nature 469: 225+.
[8]
Brown ME, Rondon E, Rajesh D, Mack A, Lewis R, et al. (2010) Derivation of Induced Pluripotent Stem Cells from Human Peripheral Blood T Lymphocytes. PLoS ONE 5: e11373.
[9]
Hanna J, Wernig M, Markoulaki S, Sun C-W, Meissner A, et al. (2007) Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin. Science 318: 1920–1923.
[10]
Meyer JS, Howden SE, Wallace KA, Verhoeven AD, Wright LS, et al. (2011) Optic Vesicle-like Structures Derived from Human Pluripotent Stem Cells Facilitate a Customized Approach to Retinal Disease Treatment. Stem Cells 29: 1206–1218.
[11]
Alipio Z, Adcock DM, Waner M, O TMJ, Fink LM, et al. (2010) Sustained factor VIII production in hemophiliac mice 1 year after engraftment with induced pluripotent stem cell-derived factor VIII producing endothelial cells. Blood Coagulation & Fibrinolysis 21: 502–504.
[12]
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. (2007) Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells. Science 318: 1917–1920.
[13]
Eggenschwiler R, Cantz T (2009) Induced pluripotent stem cells generated without viral integration. Hepatology 49: 1048–1049.
[14]
Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S (2008) Generation of Mouse Induced Pluripotent Stem Cells Without Viral Vectors. Science 322: 949–953.
[15]
Cowling R, Desai R, Gertsenstein M, Hamalainen R, Hoon-Ki S, et al. (2009) piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458: 766+.
[16]
Warren L, Manos PD, Ahfeldt T, Loh Y-H, Li H, et al. (2010) Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNA. Cell Stem Cell 7: 618–630.
[17]
Kim D, Kim C-H, Moon J-I, Chung Y-G, Chang M-Y, et al. (2009) Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins. Cell Stem Cell 4: 472–476.
[18]
Sommer C, Mostoslavsky G (2010) Experimental approaches for the generation of induced pluripotent stem cells. Stem Cell Research & Therapy 1: 26.
[19]
Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, et al. (2009) Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors. Cell 136: 964–977.
[20]
Sebastiano V, Maeder ML, Angstman JF, Haddad B, Khayter C, et al. (2011) In Situ Genetic Correction of the Sickle Cell Anemia Mutation in Human Induced Pluripotent Stem Cells Using Engineered Zinc Finger Nucleases. Stem Cells 29: 1717–1726.
[21]
Nagy A (2000) Cre recombinase: the universal reagent for genome tailoring. Genesis 26: 99–109.
[22]
Somers A, Jean J-C, Sommer CA, Omari A, Ford CC, et al. (2010) Generation of Transgene-Free Lung Disease-Specific Human Induced Pluripotent Stem Cells Using a Single Excisable Lentiviral Stem Cell Cassette. Stem Cells 28: 1728–1740.
[23]
L？hle M, Hermann A, Gla？ H, Kempe A, Schwarz SC, et al. (2012) Differentiation Efficiency of Induced Pluripotent Stem Cells Depends on the Number of Reprogramming Factors. Stem Cells 30: 570–579.
[24]
Mitalipova MM, Rao RR, Hoyer DM, Johnson JA, Meisner LF, et al. (2005) Preserving the genetic integrity of human embryonic stem cells. Nat Biotech 23: 19–20.
[25]
Davis RP, Ng ES, Costa M, Mossman AK, Sourris K, et al. (2008) Targeting a GFP reporter gene to the MIXL1 locus of human embryonic stem cells identifies human primitive streak-like cells and enables isolation of primitive hematopoietic precursors. Blood 111: 1876–1884.
[26]
Anderson D, Self T, Mellor IR, Goh G, Hill SJ, et al. (2007) Transgenic enrichment of cardiomyocytes from human embryonic stem cells. Mol Ther 15: 2027–2036.
[27]
Lee GS, Kim BS, Sheih JH, Moore M (2008) Forced expression of HoxB4 enhances hematopoietic differentiation by human embryonic stem cells. Mol Cells 25: 487–493.
[28]
Fujikura J, Yamato E, Yonemura S, Hosoda K, Masui S, et al. (2002) Differentiation of embryonic stem cells is induced by GATA factors. Genes Dev 16: 784–789.
[29]
Rideout WM 3rd, Hochedlinger K, Kyba M, Daley GQ, Jaenisch R (2002) Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell 109: 17–27.
[30]
Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, et al. (2007) Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318: 1920–1923.
[31]
Davis RP, Costa M, Grandela C, Holland AM, Hatzistavrou T, et al. (2008) A protocol for removal of antibiotic resistance cassettes from human embryonic stem cells genetically modified by homologous recombination or transgenesis. Nat Protoc 3: 1550–1558.
[32]
Schnutgen F, Stewart AF, von Melchner H, Anastassiadis K (2006) Engineering embryonic stem cells with recombinase systems. Methods Enzymol 420: 100–136.
[33]
Branda CS, Dymecki SM (2004) Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Dev Cell 6: 7–28.
[34]
Jagle U, Gasser JA, Muller M, Kinzel B (2007) Conditional transgene expression mediated by the mouse beta-actin locus. Genesis 45: 659–666.
[35]
Madisen L, Zwingman TA, Sunkin SM, Oh SW, Zariwala HA, et al. (2010) A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci 13: 133–140.
[36]
Takahashi K, Okita K, Nakagawa M, Yamanaka S (2007) Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2: 3081–3089.
[37]
Hong S, Hwang DY, Yoon S, Isacson O, Ramezani A, et al. (2007) Functional analysis of various promoters in lentiviral vectors at different stages of in vitro differentiation of mouse embryonic stem cells. Mol Ther 15: 1630–1639.
[38]
Kim SY, Lee JH, Shin HS, Kang HJ, Kim YS (2002) The human elongation factor 1 alpha (EF-1 alpha) first intron highly enhances expression of foreign genes from the murine cytomegalovirus promoter. J Biotechnol 93: 183–187.
[39]
Zufferey R, Donello JE, Trono D, Hope TJ (1999) Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 73: 2886–2892.
[40]
Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, et al. (2004) Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector. Nat Biotechnol 22: 589–594.
[41]
Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, et al. (2009) piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458: 766–770.
[42]
Carey BW, Markoulaki S, Hanna J, Saha K, Gao Q, et al. (2009) Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci U S A 106: 157–162.
[43]
Kumar M, Keller B, Makalou N, Sutton RE (2001) Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther 12: 1893–1905.
[44]
Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, et al. (1993) The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274–5283.
